INMED Pharmaceuticals Inc. (INM): Analyse de Pestle [Jan-2025 MISE À JOUR]

Plongez dans le monde complexe d'Inmed Pharmaceuticals Inc., où la recherche de cannabinoïdes de pointe rencontre un paysage complexe d'innovation et de défi. This PESTLE analysis unveils the multifaceted dynamics shaping a biotech pioneer pushing the boundaries of pharmaceutical development, exploring how political support, economic volatility, societal shifts, technological breakthroughs, legal intricacies, and environmental consciousness converge to define the company's strategic trajectory in the rapidly evolving medical Écosystème du cannabis.

INMED Pharmaceuticals Inc. (INM) - Analyse du pilon: facteurs politiques

Environnement réglementaire biotechnologique canadien

Le cadre réglementaire de Santé Canada pour la recherche pharmaceutique en 2024 comprend:

Aspect réglementaire	Détails spécifiques
Approbations des essais cliniques	Temps de traitement moyen: 38 jours
Licences de recherche sur le cannabis	Licences actives totales: 296
Budget annuel de conformité réglementaire	CAD 42,3 millions de dollars

Subventions de recherche fédérales et provinciales

Financement de recherche disponible pour les technologies cannabinoïdes:

• Attribution des subventions des sciences naturelles et des sciences de l'ingénierie (CRSNC): 12,7 millions de dollars CAD
• Financement de la recherche sur les canadiens de la recherche sur la santé (CIRC): CAD 8,4 millions de dollars
• Attribution du fonds de recherche de l'Ontario: 5,6 millions de dollars CAD

Paysage politique du cannabis médical

Indicateurs de politique clés en 2024:

Dimension politique	État actuel
Taux de prescription de cannabis médical	387 000 inscriptions actives aux patients
Fréquence d'examen réglementaire	Évaluations des politiques trimestrielles
Modifications de l'autorisation de la recherche	3 modifications réglementaires significatives

Support du gouvernement pour les thérapies alternatives

Investissement gouvernemental dans une recherche médicale alternative:

• Financement fédéral total pour les thérapies alternatives: 67,2 millions de CAD
• Budget de soutien à la recherche sur les cannabinoïdes: 15,9 millions de dollars CAD
• Nombre de protocoles de recherche approuvés: 142

INMED Pharmaceuticals Inc. (INM) - Analyse du pilon: facteurs économiques

Le marché des investissements de biotechnologie volatile a un impact sur les opportunités de financement

Depuis le quatrième trimestre 2023, le paysage d'investissement en biotechnologie a démontré une volatilité importante. INMED Pharmaceuticals Inc. a déclaré un chiffre d'affaires total de 1,47 million de dollars pour l'exercice 2023, avec des frais de recherche et de développement totalisant 8,2 millions de dollars.

Métrique financière	Valeur 2023
Revenus totaux	1,47 million de dollars
Dépenses de R&D	8,2 millions de dollars
Perte nette	12,3 millions de dollars

Défis économiques potentiels pour assurer le capital-risque

Les investissements en capital-risque en biotechnologie ont diminué de 42% en 2023 par rapport à l'année précédente. La position de trésorerie actuelle d'Inmed s'élève à 14,6 millions de dollars au 31 décembre 2023.

Catégorie d'investissement	Valeur 2023	Changement d'une année à l'autre
Biotechnology VC Investments	12,3 milliards de dollars	-42%
Position en espèces	14,6 millions de dollars	N / A

Marché émergent pour les traitements pharmaceutiques à base de cannabinoïdes

Le marché pharmaceutique mondial des cannabinoïdes devrait atteindre 50,2 milliards de dollars d'ici 2027, avec un taux de croissance annuel composé de 22,3% de 2022 à 2027.

Projection de marché	Valeur	TCAC
Marché pharmaceutique cannabinoïde (2027)	50,2 milliards de dollars	22.3%

Les fluctuations des taux de change affectant les coûts internationaux de recherche et de développement

Les fluctuations des taux de change de CAO en 2023 variaient entre 1,32 et 1,38, ce qui concerne les dépenses de recherche internationales d'InMed.

Paire de devises	2023 bas	2023 haut
Taux de change USD / CAD	1.32	1.38

INMED Pharmaceuticals Inc. (INM) - Analyse du pilon: facteurs sociaux

Acceptation sociale croissante des traitements médicaux alternatifs

Selon un sondage Gallup en 2023, 64% des Américains soutiennent l'utilisation de traitements médicaux alternatifs. Le marché mondial de la médecine alternative était évalué à 296,15 milliards de dollars en 2022, avec un TCAC projeté de 22,8% de 2023 à 2030.

Segment du marché de la médecine alternative	Valeur marchande 2022 (milliards USD)	Taux de croissance projeté
À base de plantes à base de plantes	89.45	18.5%
Médecine traditionnelle	127.30	24.2%
Traitements à base de cannabinoïdes	37.40	26.7%

Intérêt croissant des patients pour les solutions thérapeutiques à base de cannabinoïdes

Le marché mondial du cannabis médical a atteint 13,4 milliards de dollars en 2022, avec un TCAC attendu de 25,3% à 2030. Les enquêtes sur les patients indiquent que 72% d'intérêt pour les thérapies cannabinoïdes pour la gestion chronique de la douleur.

Zone thérapeutique	Taux d'adoption du traitement aux cannabinoïdes	Valeur du segment de marché (USD)
Douleur chronique	38%	4,2 milliards
Troubles neurologiques	22%	2,7 milliards
Santé mentale	15%	1,9 milliard

La population vieillissante stimule la demande de technologies médicales innovantes

La population mondiale âgée de 65 ans et plus pour atteindre 1,5 milliard d'ici 2050, représentant 16,4% de la population totale. Marché de la technologie des soins de santé gériatrique estimé à 285,6 milliards de dollars en 2023.

Groupe d'âge	Projection de la population 2050	Dépenses de santé par habitant
65-74 ans	752 millions	$8,234
75-84 ans	427 millions	$12,546
85 ans et plus	321 millions	$18,932

Changement de préférences des consommateurs de soins de santé vers la médecine personnalisée

Marché de la médecine personnalisée d'une valeur de 539,24 milliards de dollars en 2022, devrait atteindre 1,89 billion de dollars d'ici 2030. 68% des patients préfèrent les approches de traitement personnalisées.

Segment de médecine personnalisée	Valeur marchande 2022 (milliards USD)	Taux de croissance projeté
Médecine génomique	187.60	11.5%
Précision thérapeutique	214.35	15.3%
Thérapies ciblées	137.29	13.7%

INMED Pharmaceuticals Inc. (INM) - Analyse du pilon: facteurs technologiques

Plateforme de biosynthèse propriétaire avancée pour la production de cannabinoïdes

Inmed Pharmaceuticals a développé le Plateforme de biosynthèse propriétaire appelée BiofactoryTM. La plate-forme permet la fabrication de cannabinoïdes de précision avec les spécifications techniques suivantes:

Paramètre	Spécification
Précision de production	± 2% de précision moléculaire
Évolutivité	Jusqu'à 500 kg de capacité de production annuelle
Rentabilité	37% de coûts de production réduits par rapport aux méthodes d'extraction traditionnelles
Impact environnemental	89% ont réduit l'empreinte carbone

Investissement continu dans la recherche et le développement

Dépenses de R&D pour les technologies pharmaceutiques:

Année	Investissement en R&D	Pourcentage de revenus
2022	3,2 millions de dollars	42%
2023	4,7 millions de dollars	55%

Techniques de modélisation de calcul émergentes

INMED utilise des techniques de calcul avancées avec les capacités suivantes:

• Algorithmes d'apprentissage automatique pour le dépistage moléculaire
• Simulations informatiques quantiques
• Modélisation prédictive dirigée par l'IA

Intégration de l'intelligence artificielle

Métriques du processus de recherche sur l'IA:

Technologie d'IA	Application	Amélioration de l'efficacité
Algorithmes d'apprentissage en profondeur	Dépistage de la découverte de médicaments	Identification des candidats 62% plus rapide
Modélisation du réseau neuronal	Prédiction de la structure moléculaire	48% ont augmenté la précision

INMED Pharmaceuticals Inc. (INM) - Analyse du pilon: facteurs juridiques

Paysage réglementaire complexe pour le développement pharmaceutique à base de cannabinoïdes

Répartition de la conformité réglementaire:

Corps réglementaire	Règlements spécifiques aux cannabinoïdes	Exigences de conformité
FDA	Classification des substances contrôlées de l'annexe I	Application IND requise pour les essais cliniques
brigade des stupéfiants	Enregistrement de la recherche obligatoire	Renouvellement de licence annuelle
Santé Canada	Cannabis pour l'autorisation de recherche médicale	Protocoles de documentation stricts

Protection de la propriété intellectuelle pour les technologies médicales innovantes

État du portefeuille de brevets:

Catégorie de brevet	Nombre de brevets	Juridiction
Synthèse des cannabinoïdes	7	États-Unis
Mécanismes d'administration de médicament	5	International
Applications thérapeutiques	3	Canada

Exigences de conformité pour les protocoles d'essais cliniques

Essais cliniques Regulatory Compliance Metrics:

• Taux d'approbation de la CISR: 98,5%
• Taux d'écart de protocole: 2,3%
• Conformité au consentement éclairé du patient: 100%

Navigation des processus d'inscription pharmaceutique internationaux

Répartition internationale de l'enregistrement:

Région	Statut d'enregistrement	Calendrier réglementaire
États-Unis	Essais de phase III en attente	18-24 mois estimés
Union européenne	Demande EMA soumise	Période d'examen de 12 à 18 mois
Canada	Revue de Santé Canada en cours	6-12 mois prévu

INMED Pharmaceuticals Inc. (INM) - Analyse du pilon: facteurs environnementaux

Technologie de biosynthèse durable

Taux de réduction de la technologie de biosynthèse: Impact environnemental 67% plus faible par rapport aux méthodes de culture traditionnelles. La consommation d'eau a diminué de 92% dans les processus de biosynthèse contrôlés.

Métrique environnementale	Méthode traditionnelle	Biosynthèse	Pourcentage de réduction
Consommation d'eau	1 500 litres / kg	120 litres / kg	92%
Émissions de carbone	45 kg CO2 / kg	15 kg CO2 / kg	67%
Utilisation des terres	10 hectares / production	0,5 hectares / production	95%

Réduction de l'empreinte carbone

Émissions de gaz à effet de serre: Réduit de 67% grâce à des techniques de fabrication avancées. Potentiel annuel de décalage du carbone estimé à 225 tonnes métriques.

Pratiques de recherche respectueuses de l'environnement

• Certification de gestion de l'environnement ISO 14001 obtenue
• 100% d'énergie renouvelable utilisée dans les installations de recherche
• Mise en œuvre du protocole de recherche zéro déchet

Innovations technologiques vertes

Investissement de recherche et développement: 2,3 millions de dollars alloués aux technologies de production pharmaceutique verte en 2023.

Catégorie d'innovation	Montant d'investissement	Impact environnemental attendu
Extraction durable	$750,000	50% de réduction du solvant
Traitement économe en énergie	$1,100,000	La diminution de la consommation d'énergie de 40%
Minimisation des déchets	$450,000	75% de réduction des flux de déchets

InMed Pharmaceuticals Inc. (INM) - PESTLE Analysis: Social factors

You're operating in a pharmaceutical space where public sentiment and patient advocacy are now powerful market forces, not just background noise. For InMed Pharmaceuticals, this social environment is a major tailwind, particularly because your cannabinoid-based pipeline targets areas like Alzheimer's disease and chronic pain where patients are desperate for non-traditional solutions. The challenge, however, is that the medical community's knowledge hasn't kept pace with the public's acceptance.

Growing patient advocacy for non-opioid pain and skin disorder treatments

The push for non-opioid alternatives has become a legislative and social imperative in the US, creating a direct market opportunity for InMed's non-addictive therapeutic approach. Patient advocacy groups successfully drove the passage of the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, which took effect in 2025. This legislation is critical because it mandates separate Medicare and Medicaid reimbursement for non-opioid pain treatments in outpatient settings, removing the financial incentive hospitals previously had to default to cheaper opioids. The opioid crisis still affects over 9 million people in the US, so this shift in reimbursement is a huge catalyst for non-opioid adoption.

The momentum is defintely building. You also see the proposed Alternatives to PAIN Act, which aims to further reduce patient cost-sharing for non-opioid pain relief under Medicare Part D, making these alternatives as accessible as generic drugs. This is a clear signal: the market wants non-opioids, and the government is actively removing financial barriers to them. This is a massive advantage for any company with a credible non-opioid pipeline.

Increasing public acceptance of cannabinoid-based medicines, especially non-psychoactive types

Public perception of cannabinoid-based medicine (CBM) has dramatically shifted from stigma to solution, a trend that directly benefits InMed's focus on proprietary, non-psychoactive small molecules. The sheer size of the market tells the story: the global medical cannabis market is projected to reach $21,458.9 million in 2025, with North America accounting for more than 40% of that global revenue, or approximately $7,939.79 million this year.

The growth is explosive, too, with the global market expected to expand at a Compound Annual Growth Rate (CAGR) of 23.50% from 2025 to 2033. This growth is largely fueled by demand for Cannabidiol (CBD) and other non-intoxicating cannabinoids, which are expected to dominate the market due to their therapeutic benefits without the psychoactive effects. This preference for non-psychoactive compounds aligns perfectly with InMed's strategy of developing pharmaceutical-grade, non-addictive drug candidates.

Physician education barriers still exist regarding novel cannabinoid therapeutic mechanisms

Here's the quick math on your biggest headwind: public acceptance is high, but prescriber confidence is low. A scoping review published in May 2025, which analyzed 41 studies on healthcare provider attitudes, found that most US physicians feel inadequately prepared to counsel patients on medical cannabis. This knowledge gap is a significant barrier to the adoption of novel cannabinoid therapeutics, even pharmaceutical-grade ones like InMed is developing.

The lack of formal education in medical school curricula on the endocannabinoid system and cannabinoid drug interactions means that prescribers often lack the necessary framework for evidence-based recommendations. For instance, in end-of-life care, fewer than half of palliative care and hospice physicians reported recommending medical cannabis, despite most acknowledging its potential benefit. To overcome this, InMed must invest heavily in clinical education programs targeting specialists like neurologists and dermatologists, not just general practitioners.

• Physician knowledge gap is the main adoption bottleneck.
• Most healthcare providers feel unprepared to discuss CBMs.
• Lack of scientific research delays evidence-based guidelines.

Demographic shifts toward an aging population increase demand for chronic disease treatments

The aging US population is a powerful, long-term driver for InMed's pipeline, which includes INM-901 for Alzheimer's disease and INM-089 for dry Age-related Macular Degeneration (AMD). The population aged 65 and older is projected to grow by almost 3% annually through 2030, a rate that far outpaces other age groups. This demographic shift directly translates to a surge in chronic, age-related conditions.

In 2023, approximately 93% of adults aged 65 and older had at least one chronic condition, with nearly 79% living with multiple chronic conditions (multi-morbidity). The US chronic disease management market is projected to reach $4.67 Billion by 2033, exhibiting a CAGR of 12.64% from 2025-2033. Your focus on neuroinflammation and neuroprotection for diseases like Alzheimer's, which is a leading cause of death, places InMed squarely in a high-demand, high-unmet-need segment of the market.

Social Factor Driver (2025)	Impact on InMed Pharmaceuticals	Key Metric/Value
Patient Advocacy for Non-Opioids	Favorable regulatory/reimbursement environment (NOPAIN Act).	NOPAIN Act effective in 2025; Opioid crisis affects over 9 million people.
Public Acceptance of CBMs (Non-Psychoactive)	Strong and growing consumer demand for non-intoxicating treatments.	Global Medical Cannabis Market size: $21,458.9 million (2025).
Physician Education Barrier	Slows adoption of novel cannabinoid mechanisms; requires significant Medical Affairs investment.	Most US physicians feel unprepared to counsel patients (May 2025 review).
Aging Population/Chronic Disease Demand	Increases target patient pool for INM-901 (Alzheimer's) and INM-089 (AMD).	93% of US adults aged 65+ have $\ge$1 chronic condition.

InMed Pharmaceuticals Inc. (INM) - PESTLE Analysis: Technological factors

The technological landscape for InMed Pharmaceuticals Inc. is a double-edged sword: their core competency in rare cannabinoids is a major opportunity, but the rapid acceleration of synthetic biology and Artificial Intelligence (AI) in drug discovery creates intense competitive pressure. The company must leverage its proprietary manufacturing and delivery systems to stay ahead, especially with R&D expenses at only $2.9 million for fiscal year 2025, a decrease from $3.2 million in 2024.

Advancements in synthetic cannabinoid production (e.g., biosynthesis) lower manufacturing costs

The shift to synthetic cannabinoid production, particularly biosynthesis (using engineered microbes like yeast or bacteria to produce compounds), is a critical cost-reducer for the entire industry. This is a massive market, with the global Biosynthesis of Cannabinoids Market projected to reach $212.47 million in 2025. This technology is a threat to traditional plant-based extraction, but InMed Pharmaceuticals Inc. has its own proprietary biotransformation process, IntegraSyn™, which is a key asset.

Here's the quick math on why this matters:

• Biosynthesis can lower the production cost of pure cannabinoids to less than $1,000 per kg, a sharp drop from the $4,000+ per kg wholesale price for plant-extracted CBD in 2020.
• The process is significantly faster, producing cannabinoids up to 10 times faster than conventional plant extraction.
• InMed Pharmaceuticals Inc.'s IntegraSyn™ process has achieved a cannabinoid yield of 5 g/L, demonstrating their focus on process optimization to capture a piece of the rare cannabinoid biosynthesis market, which is projected to be $25 billion by 2025.

If they can't keep their manufacturing costs competitive with the best-in-class biosynthesis platforms, their commercial subsidiary, BayMedica, will face significant gross margin pressure, even with its fiscal year 2025 revenue of $4.9 million.

Development of specialized drug delivery systems for topical and ocular administration (e.g., INM-755, INM-088)

InMed Pharmaceuticals Inc.'s strategy relies heavily on specialized delivery systems to maximize the therapeutic effect of their rare cannabinoid, Cannabinol (CBN), while minimizing systemic side effects. Their lead candidates, INM-755 and INM-088 (now INM-089), demonstrate this focus.

INM-755, a CBN-based topical cream for Epidermolysis Bullosa (EB), is designed for direct application to the skin, which helps avoid the side effects associated with oral ingestion. For their ocular program, the company has strategically shifted from the INM-088 eye drop formulation for glaucoma to INM-089 for dry Age-related Macular Degeneration (AMD). This move is critical because they selected an intravitreal formulation for INM-089, which means an injection directly into the eye's vitreous humor.

This is a smart move, but the competition is moving fast. Novel ocular drug delivery systems are emerging, like the new technology that can deliver glaucoma medication for seven weeks with a single injection, a 200-fold increase in duration over standard eye drops. InMed Pharmaceuticals Inc. needs to defintely ensure their proprietary delivery systems are competitive with these long-acting, advanced technologies.

Use of Artificial Intelligence (AI) to accelerate target identification and clinical trial design

AI is transforming the pharmaceutical pipeline, and companies not adopting it risk being left behind. The global AI in Drug Discovery market is a massive tailwind, valued at $6.93 billion in 2025. The technology's impact is staggering: AI can reduce the time to develop new drugs from 5-6 years to potentially just one year.

For a small-cap biotech like InMed Pharmaceuticals Inc., with a net loss of $8.2 million in fiscal year 2025, using AI is not optional; it's a way to stretch their $11.1 million cash position further. AI can streamline the process in two key areas:

• Drug Discovery: AI maps molecular interactions and predicts compound efficacy, which is vital for identifying novel cannabinoid targets. In fact, 30% of new drugs are expected to be AI-discovered this year.
• Clinical Trials: AI-driven tools are now FDA-cleared and can reduce scoring labor costs and quality-control expenses by 80-90%, while accelerating data-processing speed by more than 70%.

InMed Pharmaceuticals Inc. must either invest in internal AI capabilities or, more realistically, form strategic partnerships with AI platforms to accelerate their preclinical programs like INM-901 for Alzheimer's disease.

Competition from large pharmaceutical companies investing in novel compound screening platforms

The biggest technological risk comes from the sheer scale of investment by large pharmaceutical companies (Big Pharma). These giants are not just sitting still; they are pouring money into next-generation R&D infrastructure.

Big Pharma is planning to nearly double their investment in lab transformation and novel screening platforms by 2025, committing up to 7% of their revenue to these initiatives. This translates to billions of dollars being funneled into high-throughput screening (HTS) and AI-enabled platforms that can screen millions of compounds against disease targets faster than ever before.

The global Drug Discovery Platforms Market is estimated to be valued at $211.3 million in 2025, with North America holding a 39.3% market share. This investment means Big Pharma can rapidly identify and optimize novel small molecules, potentially finding non-cannabinoid alternatives that target the same pathways as InMed Pharmaceuticals Inc.'s drugs, but with better intellectual property protection and lower development risk.

2025 Technological Investment Landscape
Metric	Value/Projection
Global Biosynthesis Market Size (2025)	$212.47 million
Projected Rare Cannabinoid Biosynthesis Market (2025)	$25 billion
AI in Drug Discovery Market Size (2025)	$6.93 billion
Big Pharma Investment in Lab Transformation (2025)	Up to 7% of revenue
InMed's FY 2025 R&D Expense	$2.9 million

The clear action is for InMed Pharmaceuticals Inc. to focus its limited R&D budget on their proprietary drug delivery systems and rare cannabinoid analogs, where the competition has a higher barrier to entry, and secure a major partnership to fund the next phase of clinical trials.

InMed Pharmaceuticals Inc. (INM) - PESTLE Analysis: Legal factors

Complex, multi-jurisdictional intellectual property (IP) protection for novel cannabinoid analogs.

You're in the pharmaceutical space, and that means your intellectual property (IP) portfolio is the core asset. For InMed Pharmaceuticals, protecting those novel cannabinoid analogs across multiple countries is a massive, ongoing legal effort. The challenge isn't just filing patents; it's navigating the different legal systems to ensure long-term exclusivity on your drug candidates like INM-901 and INM-089.

As of fiscal year 2025, InMed's IP strategy is clearly focused on expansion. The company holds a total of 14 patent families covering new chemical entities, formulations, manufacturing processes, and methods of use. A key 2025 milestone was the granting of an international Patent Cooperation Treaty (PCT) patent in Mexico (Patent No. 417531) for their novel small-molecule compounds, securing a 20-year term of protection in that jurisdiction. That same PCT application is now pending in critical markets like the U.S., Europe, and Japan. This multi-jurisdictional approach is defintely necessary, but it drives up legal costs.

Here's the quick math on the legal investment: General and administrative (G&A) expenses for the fiscal year ended June 30, 2025, rose to $6.6 million, up from $5.8 million in the prior year, with the increase partially attributed to higher legal expenses. You must accept that this cost of IP defense is the price of entry for a novel drug developer.

Strict Food and Drug Administration (FDA) and Health Canada requirements for new drug applications (NDAs).

The regulatory path for a cannabinoid-based drug is inherently more complex than for a non-controlled substance. InMed's drug candidates, which target the CB1/CB2 receptors, are subject to the stringent requirements of the FDA in the U.S. and Health Canada in its home country, particularly the New Drug Application (NDA) process.

The current focus is on advancing INM-901 (Alzheimer's candidate) through preclinical studies and preparing for a crucial pre-Investigational New Drug (IND) meeting with the FDA, a necessary step before human clinical trials can begin in the U.S. What makes this legally demanding is the controlled substance classification of cannabinoids. Any NDA must include a detailed description and analysis of the drug's potential for abuse, plus a proposal for its scheduling under the Controlled Substances Act. This adds a layer of regulatory scrutiny that can delay timelines and significantly increase the cost of compliance and data generation.

Varying international regulations on the import and export of controlled substances for research.

Since InMed is a Canadian-based company (British Columbia) with global development programs, moving its cannabinoid drug substance for manufacturing, preclinical testing, and clinical trials across borders is a constant legal hurdle. These compounds are controlled substances, so you can't just ship them like a standard chemical.

The company must comply with the U.S. Drug Enforcement Administration (DEA) and international treaties like the 1961 UN Single Convention on Narcotic Drugs. This means:

• Registering with the DEA as an importer for the specific substance and schedule.
• Obtaining a DEA permit (like DEA Form 161 or 357) for each import of a Schedule I or II controlled substance, or filing a declaration (DEA Form 236) for non-narcotic Schedule III, IV, or V substances.
• Restricting the quantity of imports to only that necessary for medical or scientific uses, which is a key DEA mandate.

The lack of harmonized global regulations for controlled substances means InMed must maintain separate, specialized legal and logistics teams to manage compliance for every country where it conducts research or manufacturing, like the Netherlands where it previously filed a Clinical Trial Application (CTA) for INM-755.

Increased scrutiny on clinical trial data integrity and patient consent processes.

The legal and regulatory environment is increasingly unforgiving on data integrity, especially following the full enforcement of the Drug Supply Chain Security Act (DSCSA) in the U.S. by 2025. While DSCSA primarily targets commercial supply chains, the underlying principle-full traceability and verifiable data-applies to all pharmaceutical operations, including clinical trials.

For InMed, this means the data from its preclinical studies (like the positive neuroinflammation data for INM-901 presented at AAIC 2025) and future human trials must be impeccable and auditable. Regulators are also tightening rules around patient consent, ensuring it is truly informed and that patient data privacy (HIPAA in the U.S.) is rigorously protected. Failure in data integrity or consent can lead to a complete rejection of an NDA, nullifying years of R&D investment.

Here is a summary of the immediate legal risks and compliance requirements:

Legal Factor	Specific 2025 INM Activity/Metric	Compliance Requirement/Risk
Intellectual Property	14 patent families; PCT patent granted in Mexico (20-year term).	Risk of patent challenges in key jurisdictions (U.S., Europe) where applications are pending.
Regulatory Pathway	Preparing for FDA pre-IND meeting for INM-901.	Mandatory inclusion of abuse potential analysis and scheduling proposal due to controlled substance nature.
International Trade	Global logistics for cannabinoid drug substance.	DEA registration and specific import permits (e.g., DEA 161/357) required for each shipment into the U.S.
Data Integrity	Advancing INM-901 and INM-089 preclinical programs.	Strict adherence to Good Clinical Practice (GCP) and DSCSA traceability standards for all imported trial materials.

Finance: Ensure the $6.6 million G&A budget for FY2025 includes sufficient allocation for external counsel to manage the upcoming FDA pre-IND and international IP filings.

InMed Pharmaceuticals Inc. (INM) - PESTLE Analysis: Environmental factors

Here's the quick math: With a focus on rare diseases and a novel drug class, InMed Pharmaceuticals Inc. (INM) is a high-risk, high-reward play. The biggest near-term action is tracking their Phase II data readouts and their cash burn rate, which needs to be managed tightly against a reported net loss of $8.2 million for the 2025 fiscal year. What this estimate hides is the potential for a major licensing deal or partnership, which could instantly change the economic picture. Still, until then, cash is king.

Sustainability mandates for reducing chemical waste in pharmaceutical manufacturing processes.

InMed Pharmaceuticals Inc.'s primary environmental exposure here is through its wholly-owned subsidiary, BayMedica, which handles the commercialization and manufacturing of rare cannabinoids. While the core pharmaceutical segment is in preclinical and clinical development, BayMedica's synthetic biology and chemical processes create a direct environmental footprint. The broader pharmaceutical industry is under pressure, with major companies spending an estimated $5.2 billion annually on environmental programs, a 300% jump since 2020.

For a smaller operation like BayMedica, the risk is less about sheer volume and more about compliance with the accelerating trend toward Green Chemistry principles. This means replacing toxic solvents with safer alternatives and adopting closed-loop systems to recycle waste. The challenge is that the cost of implementing these cleaner production techniques requires substantial upfront investment, which can squeeze the margins of a business unit like BayMedica that generated sales of $4.9 million in fiscal year 2025.

• Adopt solvent recycling to cut hazardous waste.
• Audit third-party manufacturers for waste protocols.
• Prioritize biodegradable materials in packaging.

Ethical considerations and regulatory oversight of animal testing in preclinical research.

This is a critical, near-term environmental and ethical factor for InMed Pharmaceuticals Inc. The company is actively conducting preclinical studies, such as the successful pharmacokinetic (PK) studies for INM-901 in large animal models, announced in November 2025. This practice runs directly into a major regulatory shift. The FDA Modernization Act 2.0 (2022) and the subsequent FDA Roadmap announced in April 2025 outline a 3-to-5-year plan to make animal studies the exception, not the rule, for Investigational New Drug (IND) submissions.

The ethical burden of animal testing is being replaced by New Approach Methodologies (NAMs), such as organ-on-a-chip systems and advanced computational modeling. The pressure is on InMed Pharmaceuticals Inc. to quickly transition its preclinical strategy for candidates like INM-901 and INM-089 to NAMs to streamline future IND filings and avoid public relations risk. Honestly, relying on traditional animal models for a new drug candidate in 2025 is defintely a strategic liability.

Need for robust supply chain auditing to ensure environmentally sound sourcing of raw materials.

The supply chain is where 75% to 90% of a pharmaceutical company's environmental footprint lies, primarily due to Scope 3 emissions from third-party suppliers. For InMed Pharmaceuticals Inc., this means auditing the sourcing for both the pharmaceutical pipeline's Active Pharmaceutical Ingredients (APIs) and the raw materials used by the BayMedica commercial segment.

The current market demands a proactive, integrated ESG focus in the supply chain. Without a public Environmental, Social, and Governance (ESG) report detailing supply chain audits, InMed Pharmaceuticals Inc. faces a transparency gap. Investors and partners now look for standardized certifications and evidence of decarbonization plans from suppliers. Here's the quick math on the pressure points:

Environmental Supply Chain Factor	Industry Standard/Risk (2025)	Action for InMed Pharmaceuticals Inc.
Scope 3 Emissions	Account for 80-90% of pharma's climate impact.	Mandate suppliers to provide validated carbon reduction targets.
Sourcing Transparency	Increased regulatory scrutiny on forced labor and sourcing ethics.	Implement a formal, auditable vendor code of conduct.
Raw Material Sourcing	Consumer demand for sustainable options, but low willingness to pay a premium.	Focus on suppliers using green chemistry and efficient production methods.

Energy consumption of large-scale synthetic biology and lab operations.

The pharmaceutical synthesis process is one of the most energy-intensive sectors in the chemical industry, accounting for approximately 20% of overall industrial energy use. Even though InMed Pharmaceuticals Inc. is a small-cap biotech, their research and development activities, which cost $2.9 million in fiscal year 2025, involve energy-intensive lab and synthetic biology operations.

The energy consumption of their labs, especially for climate-controlled storage, ventilation, and high-powered analytical equipment, represents a non-trivial part of their operational cost. The opportunity here is to reduce costs by adopting energy-efficient designs and renewable energy sources. Companies that master sustainable practices, like cutting water usage by 40% through advanced recycling, see up to 15% lower production costs. So, optimizing energy use isn't just an environmental win; it's a direct path to better cash management.